Introduction. Long-acting depot antipsychotic medication given by was developed in 1960s to simplify the medications process and conteract problems with treatment adherence. This report examines 1 day of long-acting antipsychotic therapy in admitted patients to SPDC of Rome city and Lazio. Materials and Method. A naturalistic study, multicenter trial was designed to evaluate the clinical features of patients treated with antypsychotic depot in a setting specialized in the care of patients suffering from serious long-term mental illness. Results. Of the 163 patients, 153 (94.9%) had psychotic disorder, 8 (4.9%) bipolar disorder, 1 personality disorder and 1 Obsessive-Compulsive Disorder (OCD). Patients treated with haloperidol depot were 136 (83.4%), 18 (11%) with fluphenazine depot, 5 (3.1%) with risperidone depot, 2 (1.2%) with zuclopentixol depot, 1 (0.6%) with penfluridol depot and 1 (0.6%) with perfenazine. Conclusions. The study suggests a target to depot therapy: a male patient with psychotic disorder, low compliance, low insight, instability of psychopatological status, positive symptomatology and with aggressive behaviour.
Studio naturalistico sull’impiego degli antipsicotici nella formulazione long-acting negli SPDC di Roma e del Lazio
PACITTI, FRANCESCA;IANNITELLI A;
2005
Abstract
Introduction. Long-acting depot antipsychotic medication given by was developed in 1960s to simplify the medications process and conteract problems with treatment adherence. This report examines 1 day of long-acting antipsychotic therapy in admitted patients to SPDC of Rome city and Lazio. Materials and Method. A naturalistic study, multicenter trial was designed to evaluate the clinical features of patients treated with antypsychotic depot in a setting specialized in the care of patients suffering from serious long-term mental illness. Results. Of the 163 patients, 153 (94.9%) had psychotic disorder, 8 (4.9%) bipolar disorder, 1 personality disorder and 1 Obsessive-Compulsive Disorder (OCD). Patients treated with haloperidol depot were 136 (83.4%), 18 (11%) with fluphenazine depot, 5 (3.1%) with risperidone depot, 2 (1.2%) with zuclopentixol depot, 1 (0.6%) with penfluridol depot and 1 (0.6%) with perfenazine. Conclusions. The study suggests a target to depot therapy: a male patient with psychotic disorder, low compliance, low insight, instability of psychopatological status, positive symptomatology and with aggressive behaviour.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
